Search

Your search keyword '"Appelbaum F"' showing total 334 results

Search Constraints

Start Over You searched for: Author "Appelbaum F" Remove constraint Author: "Appelbaum F" Topic bone marrow transplantation Remove constraint Topic: bone marrow transplantation
334 results on '"Appelbaum F"'

Search Results

1. New drug approvals in acute myeloid leukemia: what's the best end point?

2. Bone marrow transplantation for leukaemia--current status and strategies for improvement.

Catalog

Books, media, physical & digital resources

3. Allogeneic bone marrow transplantation in children with myelodysplastic syndrome or juvenile myelomonocytic leukemia: the Seattle experience.

4. Immunity of patients surviving 20 to 30 years after allogeneic or syngeneic bone marrow transplantation.

5. Administration of cyclosporine for 24 months compared with 6 months for prevention of chronic graft-versus-host disease: a prospective randomized clinical trial.

6. The significance of bcr-abl molecular detection in chronic myeloid leukemia patients "late," 18 months or more after transplantation.

7. Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation.

8. A proposed objective way to assess results of randomized prospective clinical trials with acute graft-versus-host disease as an outcome of interest.

9. Experiences of donors enrolled in a randomized study of allogeneic bone marrow or peripheral blood stem cell transplantation.

11. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers.

13. Relapse after allogeneic bone marrow transplantation for refractory anemia is increased by shielding lungs and liver during total body irradiation.

14. Unrelated donor marrow transplantation for acute myeloid leukemia: an update of the Seattle experience.

15. Treatment of chronic myelomonocytic leukaemia by allogeneic marrow transplantation.

16. Is there a best transplant conditioning regimen for acute myeloid leukemia?

17. Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age.

18. Second allogeneic transplantation after failure of first autologous transplantation.

19. Granulocyte colony-stimulating factor given to donors before apheresis does not prevent aplasia in patients treated with donor leukocyte infusion for recurrent chronic myeloid leukemia after bone marrow transplantation.

20. Long-term follow-up of a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide for patients receiving allogenic marrow transplants during chronic phase of chronic myeloid leukemia.

21. A phase I-II clinical trial to evaluate removal of CD4 cells and partial depletion of CD8 cells from donor marrow for HLA-mismatched unrelated recipients.

22. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology.

23. Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome.

24. Marrow ablative and immunosuppressive effects of 131I-anti-CD45 antibody in congenic and H2-mismatched murine transplant models.

25. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission.

26. Bone marrow transplantation for children less than 2 years of age with acute myelogenous leukemia or myelodysplastic syndrome.

27. Allogeneic bone marrow transplantation for myelodysplastic syndrome: outcomes analysis according to IPSS score.

28. Pharmacokinetics of cyclophosphamide and its metabolites in bone marrow transplantation patients.

29. Long-term follow-Up of a randomized trial of two irradiation regimens for patients receiving allogeneic marrow transplants during first remission of acute myeloid leukemia.

30. Retrospective analysis of infectious disease in patients who received recombinant human granulocyte-macrophage colony-stimulating factor versus patients not receiving a cytokine who underwent autologous bone marrow transplantation for treatment of lymphoid cancer.

31. Association between pretransplant interferon-alpha and outcome after unrelated donor marrow transplantation for chronic myelogenous leukemia in chronic phase.

32. Unrelated and HLA-nonidentical related donor marrow transplantation for thalassemia and leukemia. A combined report from the Seattle Marrow Transplant Team and the International Bone Marrow Transplant Registry.

34. Epitope specificity of CD44 for monoclonal antibody-dependent facilitation of marrow engraftment in a canine model.

35. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia.

36. Dose rate-dependent sparing of the gastrointestinal tract by fractionated total body irradiation in dogs given marrow autografts.

37. Reproducibility in retrospective grading of acute graft-versus-host disease after allogeneic marrow transplantation.

38. Intravenous immunoglobulin and the risk of hepatic veno-occlusive disease after bone marrow transplantation.

39. Safeguarding the administration of high-dose chemotherapy: a national practice survey by the American Society for Blood and Marrow Transplantation.

40. Effect of recombinant canine stem cell factor, a c-kit ligand, on hematopoietic recovery after DLA-identical littermate marrow transplants in dogs.

41. Allogeneic marrow transplantation for primary myelofibrosis and myelofibrosis secondary to polycythaemia vera or essential thrombocytosis.

42. Marrow transplants from unrelated donors for treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.

43. Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: the effect of leukemic burden, donor HLA-matching, and marrow cell dose.

44. Long-term follow-up of allogeneic marrow transplants in patients with aplastic anemia conditioned by cyclophosphamide combined with antithymocyte globulin.

45. Graft versus leukemia (GVL) in the therapy of acute lymphoblastic leukemia (ALL).

46. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation.

47. Detection of bcr-abl transcripts in Philadelphia chromosome-positive acute lymphoblastic leukemia after marrow transplantation.

48. Primary treatment of acquired aplastic anemia: outcomes with bone marrow transplantation and immunosuppressive therapy. Seattle Bone Marrow Transplant Team.

49. The use of radiolabeled antibodies in bone marrow transplantation for hematologic malignancies.

50. The role of radioimmunotherapy in bone marrow transplantation.